ClinicalTrials.gg
CompletedNCT01350921Updated Mar 30, 2012

Evaluation of the Drug-drug Interaction Between Ticagrelor and Venlafaxine When Taken Together in Healthy Volunteers

A Phase 1 interventional study of Ticagrelor and Venlaflaxin in Drug Drug Interaction, sponsored by AstraZeneca. Completed at 2 sites in 2 countries. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2012-03-30.

Sponsored by AstraZeneca · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
22
Ages
18 Years to 45 Years
Sex
All
01

Study summary

Study evaluates the drug-drug interaction between Ticagrelor and Venlafaxine when taken together in healthy volunteers

02

Conditions studied

  • Drug Drug Interaction

Keywords

  • phase 1
  • ticagrelor
  • venlafaxine
03

In context

Lead sponsor

AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.

Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • a weight of at least 50 kg and a between 18 to 30 kg/m2

Exclusion criteria

Exclusion Criteria:

  • History of disease or disorder as judged by the investigator
  • Any clinically significant illness, medical/surgical procedure or trauma within 4 weeks of the first administration of drug.
  • History of haemophilia, von Willebrand´s disease, lupus anticoagulant or other diseases/syndromes that may alter or increase bleeding.
  • History of previous or ongoing psychiatric disease
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
22 participants (actual)

Interventions

  • 90 mg oral immediate release tablets, single dose on days 1 and 9

  • DrugVenlaflaxin

    37.5 mg oral immediate release tablets, administered twice daily on days 4-8

06

What researchers measure

Primary outcomes

  1. area under the plasma concentration-time curve during a dosing interval (AUCτ) and observed maximum plasma concentration (Cmax)

    Venlafaxine and O-desmethylvenlafaxine (ODV) on Day 8 (after multiple dose administration of venlafaxine for 4 days) and Day 9 (after concomitant administration of venlafaxine and ticagrelor):

    Time frame: Multiple assessments during day 8 and 9.

Secondary outcomes

  1. Venlafaxine and ODV on Days 8 and 9: time to Cmax (tmax)

    Ticagrelor and AR-C124910XX on Day 1 (after single dose administration of ticagrelor) and Day 9 (after concomitant administration of venlafaxine and ticagrelor): area under the plasma concentration-time curve from zero to infinity (AUC), Cmax, tmax and apparent terminal half-life t½λz

    Time frame: Multiple assessments during day 1 and 9-11

  2. Safety and tolerability of ticagrelor and venlafaxine when given concomitantly by assessments of amount of adverse events

    Time frame: Multiple assessments from day -1 do day 12 and a single assessment at follow up visit.

07

Study locations

2 sites
  • Research Site
    Overland Park, Kansas, United States
  • Research Site
    Uppsala, Sweden
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2011, a primary completion of Mar 2012 and a completion of Mar 2012. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 9, 2011
First posted
May 10, 2011
Start
May 2011
Primary completionActual
Mar 2012
CompletionActual
Mar 2012
Last update
Mar 30, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 30, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01350921
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
May 10, 2011
Start date
May 2011
Primary completion
Mar 2012
Completion
Mar 2012
Last update
Mar 30, 2012

Study contacts

Jay Horrow, PhD
study director · AstraZeneca Wilmington
Mirjana Kujacic, PhD
study chair · AstraZeneca Mölndal
Kelli Craven, MD
principal investigator · Quintiles Kansas Overland Park US

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ticagrelor

Start the discussion